Medicines Europe Conference

Frances Zipp of Lachman Consultants to be Featured Speaker at Annual Medicines for Europe Conference

(Westbury, NY – May 2019) Lachman Consultant Services, Inc. (“Lachman Consultants”), a leading provider of expert compliance, regulatory affairs and technical services to life sciences clients worldwide, will be participating as a Conference Sponsor at the 25th annual Medicines for Europe and IGBA Conference. Entitled “Committing to Global Health – Balancing Access and Sustainability,” this year’s event is focused on generic, biosimilar and value-added medicines.

Frances Zipp, President & CEO of Lachman Consultants, will be speaking on Thursday, June 13th at 11:30 a.m. at the conference. Her presentation will be on the topic of Efficiency Gains Through International Regulatory Collaboration. “Establishing mutually-beneficial partnerships is a key factor in achieving maximum operational productivity,” states Ms. Zipp. “I look forward to sharing the knowledge and expertise that more than three decades in the Life Sciences has afforded me.” A question and answer session will follow the presentation.

The conference brings together more than 300 experts, including manufacturers, stakeholders and governments to evaluate market trends, innovative commercial strategies, challenges for the pharma sector and new opportunities to improve access to medicines for patients. Medicines For Europe will take place in Warsaw, Poland from June 12-14, at the Sofitel Warsaw Victoria. Attendees are invited to visit with Lachman Consultants on the show floor.

Lachman Consultants attendance at the annual event will be of special interest to attendees as the firm has an established presence across the European continent and is extremely well versed in both U.S. and European compliance in all aspects, including manufacturing and facilities. In addition, Lachman Consultants offers decades of experience, working with generics companies, both past and present, on a worldwide basis, gaining a deep understanding of the FDA Generics landscape in the process. The company also specializes in helping Life Science companies break into the FDA and U.S. markets by serving a broad range of compliance and regulatory needs.


The robust service capabilities for generics and biosimilars of Lachman Consultants are focused in three areas: Compliance, Regulatory Affairs, and Science & Technology. Lachman’s consultants are accomplished, experienced and highly accurate in their recommendations resulting in more timely approvals of applications and submissions. The organization is well-positioned to provide consultation and full development support for therapeutically equivalent products, from small molecules to complex biologics to combination products.

“Working on behalf of international clients, we have ability to act as U.S. agents and proactive partners to offshore entities, assisting them in communications and interactions with the U.S. Food and Drug Administration,” adds Ms. Zipp. Experts in 505(b)(2) submissions and ANDAs, Lachman Consultants works closely with sponsors in determining the most effective communication strategies and procedures regarding regulatory questions as well as the myriad of ways regulations affect submissions.

Lorem ipsum dolor sit amet, consecte tur adipiscing elit. Ut eu nisl quis augue suscipit dignissim.